

MEDIA RELEASE • MEDIA RELEASE • MEDIA RELEASE

New online presentations on IBR & MLVs available to veterinarians for CE credits

Greensboro, N.C. August 27, 2013 — Continuing education credit opportunities are now available online for reviewing lectures focused on alarming new research about the potential negative effects of Infectious Bovine Rhinotracheitis (IBR) Modified-Live Vaccines (MLVs) on reproductive performance in beef and dairy cattle.

The presentations were captured at the 2013 Western Veterinary Conference Seminar, and provide insights into IBR MLVs and reproduction from every angle — university studies, lab diagnostics and on-farm findings. Topics and speakers include:

- Overview of IBR and Effects on Reproduction — Dr. Chris Chase, DVM, MS, Ph.D., professor, South Dakota State University
- Diagnostics of IBR Abortions — Dr. Donal O'Toole, MVB, Ph.D., professor, Department of Veterinary Science, University of Wyoming
- Evaluation of Current Vaccines — Dr. Robert Fulton, DVM, MS, Ph.D., professor, Oklahoma State University
- Are We Really Protecting the Cow with Current Vaccination Programs? — Dr. Bob Corbett, Dairy Health Consultation

To view the presentations and receive continuing education credits made available by Novartis Animal Health, login at <https://videoapp.eventkaddy.net> and easily create an account. Once an account is created, veterinarians can select a specific presentation to view, or view all four, at their leisure. For viewing the presentation, followed by completing a brief quiz at the end, 1 CE credits per presentation are available. There are a total of 4 CE credits available.

To learn more about the potential adverse effects of vaccinating breeding females with IBR MLVs and the alternatives available for veterinarians and producers today, visit www.virashield.com.

About Novartis Animal Health US, Inc.

Headquartered in Greensboro, NC, Novartis Animal Health US, Inc. researches, develops and commercializes leading animal treatments that meet the needs of pet owners, farmers and veterinarians. Part of the Basel, Switzerland-based Novartis Animal Health global organization, the US business is the largest of the 40 countries where Novartis Animal Health operates. For more information about Novartis Animal Health US, Inc., please consult <http://www.ah.novartis.us>.

About Novartis

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout

the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 131,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit <http://www.novartis.com>.

Novartis is on Twitter. Sign up to follow @Novartis at <http://twitter.com/novartis>.

###

Novartis Media Relations

Julie Groce
Novartis Animal Health US, Inc.
+1 336 387 1080 (direct)
+1 336 601 8079 (mobile)
julie.groce@novartis.com

Vira Shield is a registered trademark of Novartis AG, Basel, Switzerland.